Shares of NLTX stock opened at $4.88 on Tuesday. The business has a 50 day simple moving average of $3.43. The company has a quick ratio of 26.35, a current ratio of 26.35 and a debt-to-equity ratio of 0.01. Neoleukin Therapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $6.59.
Neoleukin Therapeutics (NASDAQ:NLTX) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.40).
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.
Recommended Story: What is Elliott Wave theory?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.